Investing.com -- Morgan Stanley upgraded its rating on Zealand Pharma (NASDAQ: ZEAL) shares to Overweight from Equal Weight, ...

Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment. Zealand Pharma remains on track to initiate ...

In addition, William Blair has initiated coverage on Zealand Pharma with a Market Perform rating, acknowledging the potential of its lead drug candidate, petrelintide, in the obesity market.

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma ... on long-acting amylin analogue petrelintide, which recently generated positive ...

In addition, William Blair has initiated coverage on Zealand Pharma with a Market Perform rating, acknowledging the potential of its lead drug candidate, petrelintide, in the obesity market. The firm ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...

Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...

Company announcement - No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 20, 2025 - Zealand Pharma A/S ("Zealand") (NA ...